Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 649: Nivolumab combinations in gastric/GEJ cancer
NCT02872116Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of nivolumab in gastric cancer (GC), gastroesophageal junction cancer and esophageal adenocarcinoma (EAC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall Survival up to 17 months and Progression-Free Survival up to 10 months. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction canceresophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02872116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872116.